Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - nadroparin calcium - solution for injection in pre-filled syringe - 11,400 i.u. anti-xa/0.6 millilitre(s) - heparin group; nadroparin

Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - nadroparin calcium - solution for injection in pre-filled syringe - 15,200 i.u.anti-xa/0.8 millilitre(s) - heparin group; nadroparin

Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - nadroparin calcium - solution for injection in pre-filled syringe - 19,000 international unit(s)/millilitre - heparin group; nadroparin

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - nadroparin calcium - solution for injection in pre-filled syringe - 15,200 i.u.anti-xa/0.8 millilitre(s) - heparin group; nadroparin

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - nadroparin calcium - solution for injection in pre-filled syringe - 11,400 i.u. anti-xa/0.6 millilitre(s) - heparin group; nadroparin

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - nadroparin calcium - solution for injection in pre-filled syringe - 19,000 international unit(s)/millilitre - heparin group; nadroparin

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - ethinylestradiol; levonorgestrel - tablet - 100/20 microgram(s) - progestogens and estrogens, fixed combinations; levonorgestrel and ethinylestradiol

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

accord healthcare sdn.bhd. - teriparatide -

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

smacco flo (t) limited, tanzania - pipette -

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - venetoclax - film coated tablets - venetoclax 10 mg - venetoclax - chronic lymphocytic leukemia/small lymphocytic lymphomavenclexta in combination with rituximab or as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll), who have received at least one prior therapy.venclexta in combination with obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll).acute myeloid leukemiavenclexta in combination with a hypomethylating agent or in combination with low dose cytarabine is indicated for newly diagnosed patients with acute myeloid leukemia (aml) who are ineligible for intensive chemotherapy.